$647 Million is the total value of Cormorant Asset Management, LP's 71 reported holdings in Q1 2015. The portfolio turnover from Q4 2014 to Q1 2015 was 42.9% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ALKS | Buy | ALKERMES PLC | $42,679,000 | +62.0% | 700,000 | +55.6% | 6.60% | +62.3% |
| EGRX | Buy | EAGLE PHARMACEUTICALS INC | $30,014,000 | +384.1% | 716,500 | +79.1% | 4.64% | +385.1% |
| BMY | Buy | BRISTOL MYERS SQUIBB CO | $29,606,000 | +100.6% | 459,000 | +83.6% | 4.58% | +101.0% |
| QTNT | Buy | QUOTIENT LTD | $19,025,000 | -3.9% | 1,119,100 | +1.7% | 2.94% | -3.7% |
| HRTX | Buy | HERON THERAPEUTICS INC | $18,479,000 | +162.4% | 1,270,000 | +81.4% | 2.86% | +163.0% |
| ADXS | Buy | ADVAXIS INC | $14,084,000 | +109.5% | 975,375 | +16.2% | 2.18% | +109.8% |
| ALDR | Buy | ALDER BIOPHARMACEUTICALS INC | $9,162,000 | +26.0% | 317,475 | +27.0% | 1.42% | +26.3% |
| EPRSQ | Buy | EPIRUS BIOPHARMACEUTICALS IN | $8,025,000 | +1788.2% | 896,600 | +1095.5% | 1.24% | +1778.8% |
| PFNX | New | PFENEX INC | $7,570,000 | – | 474,900 | +100.0% | 1.17% | – |
| AGEN | Buy | AGENUS INC | $7,228,000 | +127.6% | 1,409,000 | +76.1% | 1.12% | +128.0% |
| FWP | Buy | FORWARD PHARMA A/Ssponsored adr | $7,222,000 | +131.1% | 255,000 | +70.0% | 1.12% | +131.5% |
| CRIS | Buy | CURIS INC | $6,317,000 | +601.9% | 2,632,000 | +338.7% | 0.98% | +602.2% |
| NERV | Buy | MINERVA NEUROSCIENCES INC | $5,725,000 | +443.2% | 1,145,043 | +554.3% | 0.88% | +442.9% |
| LBIO | New | LION BIOTECHNOLOGIES INC | $5,145,000 | – | 424,815 | +100.0% | 0.80% | – |
| EPZM | New | EPIZYME INC | $5,000,000 | – | 266,250 | +100.0% | 0.77% | – |
| LPCN | New | LIPOCINE INC NEW | $4,600,000 | – | 666,666 | +100.0% | 0.71% | – |
| AGRX | Buy | AGILE THERAPEUTICS INC | $1,688,000 | +83.3% | 182,053 | +21.4% | 0.26% | +83.8% |
| ASND | New | ASCENDIS PHARMA A Ssponsored adr | $1,067,000 | – | 61,500 | +100.0% | 0.16% | – |
| VCYT | Buy | VERACYTE INC | $984,000 | +1.7% | 135,190 | +34.9% | 0.15% | +2.0% |
| CLLS | New | CELLECTIS S Asponsored ads | $865,000 | – | 25,000 | +100.0% | 0.13% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2015-05-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| QUOTIENT LTD | 30 | Q3 2021 | 4.3% |
| ASCENDIS PHARMA A/S | 30 | Q4 2022 | 4.8% |
| MINERVA NEUROSCIENCES INC | 29 | Q3 2021 | 4.4% |
| ACCELERON PHARMA INC | 28 | Q2 2021 | 3.4% |
| OMEROS CORP | 27 | Q3 2021 | 6.5% |
| MIRATI THERAPEUTICS INC | 25 | Q4 2022 | 7.6% |
| BLUEPRINT MEDICINES CORP | 25 | Q3 2021 | 3.6% |
| APELLIS PHARMACEUTICALS INC | 24 | Q3 2023 | 8.6% |
| NEUROCRINE BIOSCIENCES INC | 24 | Q1 2020 | 4.6% |
| ROCKET PHARMACEUTICALS, INC | 23 | Q3 2023 | 2.4% |
View Cormorant Asset Management, LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Ambrx Biopharma Inc. | March 13, 2023 | 42,771,365 | - |
| Altimmune, Inc. | February 14, 2023 | 2,600,000 | - |
| Arcellx, Inc. | February 14, 2023 | 2,075,000 | - |
| BioAtla, Inc. | February 14, 2023 | 2,499,250 | - |
| Eledon Pharmaceuticals, Inc. | February 14, 2023 | 1,391,663 | - |
| GreenLight Biosciences Holdings, PBC | February 14, 2023 | 4,751,020 | - |
| Prometheus Biosciences, Inc. | February 14, 2023 | 700,000 | - |
| Tango Therapeutics, Inc. | February 14, 2023 | 1,000,000 | - |
| VectivBio Holding AG | February 14, 2023 | 1,515,087 | - |
| Viridian Therapeutics, Inc.\DE | February 14, 2023 | 1,100,000 | - |
View Cormorant Asset Management, LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-05-08 |
| SC 13G | 2024-04-29 |
| 4 | 2024-04-22 |
| SC 13G/A | 2024-04-15 |
| 4 | 2024-04-03 |
| SC 13G | 2024-03-21 |
| 4 | 2024-03-18 |
| SC 13G/A | 2024-03-18 |
| 4 | 2024-03-11 |
| 13F-HR | 2024-02-14 |
View Cormorant Asset Management, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.